Interstitial Pulmonary Fibrosis (IPF) Bleomycin-Induced Lung Fibrosis
In rodents, a single intratracheal administration of Bleomycin leads to a well characterised response of 7-10 days of neutrophilic inflammation followed by a fibrotic response from around day 10 following bleomycin administration.
Currently there are only 2 approved drugs, that have been shown to slow the progression of Interstitial Pulmonary Fibrosis (IPF), nintedanib and pirfenidone.
Significant decreases in PV loops following bleomycin administration (Day 0) at Day 21, partially attenuated by therapeutic Pirfenidone Treatment
SD rat, C57BL/6J mouse
|Bleomycin induced fibrosis (single intratracheal administration)
|Assessing the efficacy of new compounds to slow the progression of IPF
|Daily Bodyweights and Clinical Signs, Lung Function (Resistance, Compliance, PV Loops), BAL differential cell counts, Bal TGF-β, BAL cytokines, Lung Hydroxyproline, Ashcroft Scoring and Pathology
Study data generated by Labcorp Huntingdon Pharmacology.